| CONTACT: Richard R. Current,
Vice President & CFO ,
517/372-9200 |
Neogen reports 21%
increase in net income
LANSING, Mich., Sept. 24, 2003 –
Neogen Corporation (Nasdaq: NEOG) announced today that net income
for the first quarter of its 2004 fiscal year, which ended Aug.
31, was 21% higher than the previous year’s first quarter.
Net income per share was $0.20 for the first quarter as compared
with $0.17 for the same period last year. Neogen’s quarterly
net income increased to $1,302,000 from $1,075,000 in FY 2003. The
quarter marked the 42nd consecutive profitable quarter from operations
for the Company, and was the 47th of the past 51 quarters when Neogen
reported revenue increases as compared with the previous year.Neogen’s
first quarter revenues were $12,233,000 — the first time the
Company’s first quarter revenues have exceeded $12 million.
Revenues were 10% greater than last year’s comparable quarter
of $11,154,000.“The first quarter was a great start for our
new fiscal year as we continue to deliver on our belief that trust
is earned,” said James Herbert, Neogen’s president.
“Several months ago we foresaw a period of deflation in a
number of the markets we serve, and implemented a strategy of further
reducing costs in those markets. The improvement in profitability
that we are reporting today reflects our efforts to reduce operating
expenses. In a deflationary economy, the low-cost producer ultimately
wins.” Neogen’s Food Safety Division first quarter revenues
were up 14% compared to the prior year, with broad-based increases
across many product groups and market segments. Sales of test kits
to detect mycotoxins in feed and food products increased 16% as
sporadic outbreaks are reported in the 2003 growing season, and
the effects of last year’s widespread outbreak of aflatoxin
continue to be felt. Strengthening regulatory activity also influenced
the quarter’s performance, as sales of tests to detect fumonisin,
a mold toxin primarily found in corn, more than doubled prior year
levels. The FDA recently issued guidance on the maximum safe levels
of fumonisin in corn for human food and animal feed. Sales of Neogen’s
test kits to detect food allergens, including peanut, egg, almond
and milk residues, continued their substantial growth trend by increasing
45% in the first quarter on a year-to-year comparison. Working closely
with the respected University of Nebraska’s Food Allergy Research
and Resource Program (FARRP), Neogen pioneered rapid tests for food
allergens, and is the recognized leader in the development and marketing
of diagnostic tests to detect food allergens. Unlabeled food allergens
were the cause of over half of the food recalls last year.
Neogen recently unveiled the first in a new generation of food allergen
tests. Reveal® for Peanut Allergen combines the accuracy of
previous generations of rapid food allergen screening tests with
the simplicity and speed of a dipstick test format. Tests for other
food allergens in the Reveal dipstick test format are currently
being developed.“Developing a quicker and easier test for
peanuts is an example of Neogen responding to the escalating and
evolving testing needs of the food industry,” said Ed Bradley,
Neogen’s vice president of Food Safety Sales and Marketing.
“Our continual introduction of new test kits from our research
and development efforts, and the improvement in our existing tests,
solidifies our standing as the single-source provider of testing
products to the food industry.”In the first quarter, revenues
from Neogen’s Animal Safety Division gained momentum, improving
5% over the comparable prior year quarter. The division’s
improvement was led by sales of veterinary instruments, primarily
to the retail segment of the rebounding livestock market. Neogen
continues its strategy of increasing distribution through the nation’s
retail farm store chains. In the first quarter, 13 new stores were
added, bringing the total to 766 stores.“We are very pleased
to see the improving numbers reflect our ongoing strategy of broadening
the focus of our animal safety sales and marketing efforts,”
said Lon Bohannon, Neogen’s chief operating officer. “The
continuing trust that our veterinary instruments are receiving with
farmers and ranchers is evidenced by the significant improvements
we are seeing in the same-store reordering patterns throughout the
retail segment.”In the first quarter, for the second consecutive
year, Neogen was named to Fortune Small Business’ list of
the 100 fastest-growing, publicly-held small businesses in America.
The publication ranked companies based on three criteria: earnings
growth, revenue growth and stock performance over the past three
years. The three criteria were then averaged to create the final
list. For the period of March 1, 2000 to Feb. 28, 2003, Neogen had
an average annual revenue growth rate of 19%, average annual increase
in net income of 24%, and average annual increase in its stock price
of 19%. Neogen’s growth in operating income during the same
three-year period averaged 35%.Neogen Corporation develops and markets
products dedicated to food and animal safety. The Company’s
Food Safety Division markets dehydrated culture media, and diagnostic
test kits to detect foodborne bacteria, natural toxins, genetic
modifications, food allergens, drug residues, plant diseases and
sanitation concerns. Neogen’s Animal Safety Division markets
a complete line of diagnostics, veterinary instruments, veterinary
pharmaceuticals and nutritional supplements.
NEOGEN CORPORATION
SUMMARIZED UNAUDITED CONSOLIDATED OPERATING DATA
(In thousands, except for per share)
| |
Quarter
ended Aug. 31 |
| |
2003 |
2002
(1) |
| Revenue |
|
|
| Food Safety |
$6,899 |
$6,067 |
| Animal
Safety |
5,334 |
5,087 |
| Total
revenue |
12,233 |
11,154 |
| Cost of
sales |
5,973 |
5,071 |
Gross margin
|
6,260 |
6,083 |
| Other expenses |
|
|
| Sales &
marketing |
2,923 |
2,829 |
| Administrative |
787 |
1,060 |
| Research
& development |
676 |
655 |
| Total other
expenses |
4,386 |
4,544 |
| Operating
income |
1,874 |
1,539 |
| Other revenue |
109 |
128 |
| Income
before tax |
1,983 |
1,667 |
| Income
tax |
681 |
592 |
| Net
income |
$1,302 |
$1,075 |
| Net
income per diluted share |
$0.20 |
$0.17 |
| Other information: |
|
|
| Shares
to calculate per share |
6,569 |
6,365 |
| Depreciation
& amortization |
$301 |
$300 |
| Interest
expense |
- |
- |
| Gross margin
(% of sales) |
51.20% |
54.50% |
| Operating
income (% of sales) |
15.30% |
13.80% |
| Revenue
increase vs. FY 2003 |
9.70% |
|
| Net income
increase vs. FY 2003 |
21.10% |
|
| |
|
|
NEOGEN CORPORATION SUMMARIZED UNAUDITED CONSOLIDATED BALANCE SHEET
DATA
(In thousands)
| |
Aug.
31 2003 |
May
31 2003 |
| Assets |
|
|
| Current
assets |
|
|
| Cash &
investments |
$8,632 |
$8,897 |
| Accounts
receivable |
7,172 |
7,499 |
| Inventory |
10,303 |
9,840 |
| Other current
assets |
2,026 |
1,735 |
| Total current
assets |
28,133 |
27,971 |
| Property
& equipment |
4,767 |
4,640 |
| Goodwill
& other assets |
15,316 |
15,425 |
| Total assets |
$48,216 |
$48,036 |
| Liabilities
& Stockholders’ Equity |
|
|
| Current
liabilities |
|
|
| Accounts
payable |
$1,960 |
$3,273 |
| Other current
liabilities |
2,540 |
2,490 |
| Total current
liabilities |
4,500 |
5,763 |
| Other liabilities |
870 |
871 |
Stockholders’
equity—shares out
6,269 in ‘04 & 6,200 in ‘03 |
42,846 |
41,402 |
| Total liabilities
& stockholders’ equity |
$48,216 |
$48,036 |
(1) 2002 revenues have been revised from amounts
previously reported to conform with 2003 classifications that include
shipping charges to customers as revenues.
Certain portions of this news release that do not relate to historical
financial information constitute
forward-looking statements. These forward-looking statements are
subject to certain risks and
uncertainties. Actual future results and trends may differ materially
from historical results or those
expected depending on a variety of factors listed in Management’s
Discussion and Analysis of
Financial Condition and Results of Operations in the Company’s
most recently filed Form 10-K.
|